The role of rituximab in the treatment of ANCA-associated vasculitides (AAV)
The antineutrophil cytoplasmic antibody (ANCA) associated vasculitides (AAV) are a group of primary vasculitides that affect predominantly small- to medium-sized blood vessels. AAV include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with p...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SMW supporting association (Trägerverein Swiss Medical Weekly SMW)
2015-01-01
|
| Series: | Swiss Medical Weekly |
| Subjects: | |
| Online Access: | https://www.smw.ch/index.php/smw/article/view/1980 |
| _version_ | 1811288509287235584 |
|---|---|
| author | Thomas Daikeler Andreas D. Kistler Pierre-Yves Martin Bruno Vogt Uyen Huynh-Do |
| author_facet | Thomas Daikeler Andreas D. Kistler Pierre-Yves Martin Bruno Vogt Uyen Huynh-Do |
| author_sort | Thomas Daikeler |
| collection | DOAJ |
| description |
The antineutrophil cytoplasmic antibody (ANCA) associated vasculitides (AAV) are a group of primary vasculitides that affect predominantly small- to medium-sized blood vessels. AAV include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA). Disease severity is dictated by the location and extent of the blood vessels affected. If left untreated, systemic forms of AAV are often fatal. The advent of immunosuppressive therapy (cyclophosphamide plus glucocorticoids) has revolutionised the prognosis for patients with AAV, transforming the course of the disease from fatal to one that can be managed, though not without significant treatment-related toxicity. Recently, the monoclonal antibody rituximab was approved for the treatment of GPA and MPA, providing the first major alternative to cyclophosphamide for induction therapy of AAV. This review explores the emerging role of rituximab in the management of this complex disorder.
|
| first_indexed | 2024-04-13T03:38:17Z |
| format | Article |
| id | doaj.art-9f9b32413dee44fc818901190436544a |
| institution | Directory Open Access Journal |
| issn | 1424-3997 |
| language | English |
| last_indexed | 2024-04-13T03:38:17Z |
| publishDate | 2015-01-01 |
| publisher | SMW supporting association (Trägerverein Swiss Medical Weekly SMW) |
| record_format | Article |
| series | Swiss Medical Weekly |
| spelling | doaj.art-9f9b32413dee44fc818901190436544a2022-12-22T03:04:16ZengSMW supporting association (Trägerverein Swiss Medical Weekly SMW)Swiss Medical Weekly1424-39972015-01-01145050610.4414/smw.2015.14103The role of rituximab in the treatment of ANCA-associated vasculitides (AAV)Thomas DaikelerAndreas D. KistlerPierre-Yves MartinBruno VogtUyen Huynh-Do The antineutrophil cytoplasmic antibody (ANCA) associated vasculitides (AAV) are a group of primary vasculitides that affect predominantly small- to medium-sized blood vessels. AAV include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA). Disease severity is dictated by the location and extent of the blood vessels affected. If left untreated, systemic forms of AAV are often fatal. The advent of immunosuppressive therapy (cyclophosphamide plus glucocorticoids) has revolutionised the prognosis for patients with AAV, transforming the course of the disease from fatal to one that can be managed, though not without significant treatment-related toxicity. Recently, the monoclonal antibody rituximab was approved for the treatment of GPA and MPA, providing the first major alternative to cyclophosphamide for induction therapy of AAV. This review explores the emerging role of rituximab in the management of this complex disorder. https://www.smw.ch/index.php/smw/article/view/1980rituximabfirst-line treatmentrelapsed/refractory diseasecyclophosphamideglucocorticoidsmethotrexate |
| spellingShingle | Thomas Daikeler Andreas D. Kistler Pierre-Yves Martin Bruno Vogt Uyen Huynh-Do The role of rituximab in the treatment of ANCA-associated vasculitides (AAV) Swiss Medical Weekly rituximab first-line treatment relapsed/refractory disease cyclophosphamide glucocorticoids methotrexate |
| title | The role of rituximab in the treatment of ANCA-associated vasculitides (AAV) |
| title_full | The role of rituximab in the treatment of ANCA-associated vasculitides (AAV) |
| title_fullStr | The role of rituximab in the treatment of ANCA-associated vasculitides (AAV) |
| title_full_unstemmed | The role of rituximab in the treatment of ANCA-associated vasculitides (AAV) |
| title_short | The role of rituximab in the treatment of ANCA-associated vasculitides (AAV) |
| title_sort | role of rituximab in the treatment of anca associated vasculitides aav |
| topic | rituximab first-line treatment relapsed/refractory disease cyclophosphamide glucocorticoids methotrexate |
| url | https://www.smw.ch/index.php/smw/article/view/1980 |
| work_keys_str_mv | AT thomasdaikeler theroleofrituximabinthetreatmentofancaassociatedvasculitidesaav AT andreasdkistler theroleofrituximabinthetreatmentofancaassociatedvasculitidesaav AT pierreyvesmartin theroleofrituximabinthetreatmentofancaassociatedvasculitidesaav AT brunovogt theroleofrituximabinthetreatmentofancaassociatedvasculitidesaav AT uyenhuynhdo theroleofrituximabinthetreatmentofancaassociatedvasculitidesaav AT thomasdaikeler roleofrituximabinthetreatmentofancaassociatedvasculitidesaav AT andreasdkistler roleofrituximabinthetreatmentofancaassociatedvasculitidesaav AT pierreyvesmartin roleofrituximabinthetreatmentofancaassociatedvasculitidesaav AT brunovogt roleofrituximabinthetreatmentofancaassociatedvasculitidesaav AT uyenhuynhdo roleofrituximabinthetreatmentofancaassociatedvasculitidesaav |